Kisspeptin-10

Price and cost-per-mg comparison

Kisspeptin-10 is a 10-amino-acid C-terminal fragment of the KISS1-derived peptide family, which serves as the primary upstream regulator of GnRH pulsatility in the hypothalamus. By binding to the KISS1R receptor on GnRH neurons, kisspeptin-10 triggers GnRH release and downstream LH and FSH secretion, positioning it as a master regulator of the reproductive neuroendocrine axis. Peer-reviewed human studies demonstrate that kisspeptin administration evokes LH pulse generation and modulates gonadotropin secretion in both healthy volunteers and individuals with reproductive dysfunction, including polycystic ovary syndrome. Kisspeptin-10 is an investigational peptide actively studied in clinical research; it is not approved by the FDA for any therapeutic indication and is not available as a licensed pharmaceutical. Kisspeptin-10 research contexts: clinical studies at Imperial College London and other institutions have characterized kisspeptin-10 pharmacology in human subjects across multiple reproductive contexts. In women, kisspeptin administration has been studied for ovulation triggering in IVF protocols as an alternative to hCG, with phase 2 trial data supporting its effectiveness for oocyte maturation while potentially reducing ovarian hyperstimulation syndrome risk. In men with hypogonadotropic hypogonadism, kisspeptin-10 infusion protocols have been studied to characterize LH pulse deficits and assess reproductive axis recovery. The peptide's upstream position in the GnRH axis — above gonadorelin, hCG, and downstream gonadotropins — makes it a research tool for understanding the root causes of hypothalamic-level reproductive dysfunction. Kisspeptin-10 vs kisspeptin-54: the two forms differ in length and pharmacokinetic profile. Kisspeptin-54 is the full 54-amino-acid peptide with a longer half-life in circulation; kisspeptin-10 is the truncated, most biologically active fragment. Human studies have used both forms depending on the research objective — kisspeptin-10 for acute LH pulse characterization, kisspeptin-54 for sustained gonadotropin studies. Neither is commercially available as an approved therapeutic. Fertility-focused telehealth providers and reproductive hormone specialists are listed in the PeptideBase directory. [Women's health addendum] Subcutaneous kisspeptin-54 has been studied in Phase 2 randomized controlled trials as an oocyte-maturation trigger during IVF, with a favorable OHSS-risk profile relative to hCG triggers, but remains investigational and is not FDA-approved for this or any indication. Chronic/repeated kisspeptin administration causes receptor tachyphylaxis in controlled human dosing studies, so it is not evidenced as a cycle-restoring or fertility-maintenance therapy. Kisspeptin's role in menopause and pregnancy/lactation is mechanistic only — no human administration-safety data exist for either context.

91 listings · 62 vendors · updated 28 Sept 2026 · how prices are computed · educational only, not medical advice